DE3875700T2 - Wirkstoff - monoklonale antikoerper - konjugate. - Google Patents

Wirkstoff - monoklonale antikoerper - konjugate.

Info

Publication number
DE3875700T2
DE3875700T2 DE8888119419T DE3875700T DE3875700T2 DE 3875700 T2 DE3875700 T2 DE 3875700T2 DE 8888119419 T DE8888119419 T DE 8888119419T DE 3875700 T DE3875700 T DE 3875700T DE 3875700 T2 DE3875700 T2 DE 3875700T2
Authority
DE
Germany
Prior art keywords
drug
group
substituted
carbon atoms
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888119419T
Other languages
German (de)
English (en)
Other versions
DE3875700D1 (de
Inventor
Peter D Senter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE3875700D1 publication Critical patent/DE3875700D1/de
Application granted granted Critical
Publication of DE3875700T2 publication Critical patent/DE3875700T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
DE8888119419T 1987-11-23 1988-11-22 Wirkstoff - monoklonale antikoerper - konjugate. Expired - Fee Related DE3875700T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/124,313 US4952394A (en) 1987-11-23 1987-11-23 Drug-monoclonal antibody conjugates

Publications (2)

Publication Number Publication Date
DE3875700D1 DE3875700D1 (de) 1992-12-10
DE3875700T2 true DE3875700T2 (de) 1993-03-18

Family

ID=22414122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888119419T Expired - Fee Related DE3875700T2 (de) 1987-11-23 1988-11-22 Wirkstoff - monoklonale antikoerper - konjugate.

Country Status (16)

Country Link
US (1) US4952394A (2)
EP (1) EP0317957B1 (2)
JP (1) JPH02111731A (2)
KR (1) KR910005887B1 (2)
AT (1) ATE81986T1 (2)
AU (1) AU617380B2 (2)
CA (1) CA1303524C (2)
DE (1) DE3875700T2 (2)
DK (1) DK651088A (2)
FI (1) FI885361A7 (2)
GR (1) GR3006211T3 (2)
IL (1) IL88428A0 (2)
NO (1) NO169958C (2)
NZ (1) NZ226955A (2)
PT (1) PT89062B (2)
ZA (1) ZA886811B (2)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
ATE412769T1 (de) * 1994-04-05 2008-11-15 Morre D James Nadh-oxidase als zielmolekül in diagnose und therapie
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
JP2002542386A (ja) * 1999-04-23 2002-12-10 アルザ・コーポレーション 放出可能な結合及びこれを含む組成物
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
AU2001227679A1 (en) * 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
WO2001071352A2 (en) * 2000-03-17 2001-09-27 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
JP2004514409A (ja) * 2000-05-10 2004-05-20 ブリストル−マイヤーズ　スクイブ　カンパニー 修飾イノシン５’−一リン酸デヒドロゲナーゼポリペプチドおよびその用途
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
KR20070053214A (ko) * 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
JP2008529556A (ja) * 2005-02-18 2008-08-07 メダレックス， インク． 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
RS52100B (sr) 2005-10-26 2012-06-30 Medarex, Inc. Postupci i jedinjenja za pripremu analoga cc-1065
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
AR065404A1 (es) * 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US8463365B2 (en) * 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
CA2998948A1 (en) 2008-05-27 2009-12-17 Genzyme Corporation Peptide analogs of alpha-melanocyte stimulating hormone
BRPI0923155A2 (pt) 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
WO2016072938A1 (en) 2014-11-05 2016-05-12 Nanyang Technological University Stabilized and autonomous antibody vh domain
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2019152806A1 (en) 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
EP4182475A2 (en) 2020-07-17 2023-05-24 Onena Medicines S.L. Antibodies against lefty proteins
EP4079327A1 (en) * 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
WO2024064752A2 (en) 2022-09-20 2024-03-28 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
EP4642488A1 (en) 2022-12-27 2025-11-05 Yale University Antibody drug conjugates
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
EP4683674A1 (en) 2023-03-23 2026-01-28 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound

Also Published As

Publication number Publication date
FI885361L (fi) 1989-05-24
NO885199D0 (no) 1988-11-22
JPH02111731A (ja) 1990-04-24
ZA886811B (en) 1989-07-26
DE3875700D1 (de) 1992-12-10
IL88428A0 (en) 1989-06-30
DK651088D0 (da) 1988-11-22
NO885199L (no) 1989-05-24
KR910005887B1 (ko) 1991-08-06
PT89062B (pt) 1993-07-30
FI885361A7 (fi) 1989-05-24
EP0317957A3 (en) 1989-07-05
DK651088A (da) 1989-05-24
GR3006211T3 (2) 1993-06-21
NZ226955A (en) 1991-11-26
CA1303524C (en) 1992-06-16
EP0317957A2 (en) 1989-05-31
NO169958C (no) 1992-08-26
NO169958B (no) 1992-05-18
ATE81986T1 (de) 1992-11-15
FI885361A0 (fi) 1988-11-18
PT89062A (pt) 1989-11-30
EP0317957B1 (en) 1992-11-04
AU617380B2 (en) 1991-11-28
AU2582488A (en) 1989-05-25
KR890007724A (ko) 1989-07-05
US4952394A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
DE3875700T2 (de) Wirkstoff - monoklonale antikoerper - konjugate.
DE69131435T2 (de) Bifunktionale Kupplungsverbindungen, Konjugate und Verfahren zu ihrer Herstellung
DE68915179T2 (de) Anthracyclin-Immunokonjugate mit neuem Spacer und Verfahren zu deren Herstellung.
DE69626849T2 (de) Verzweigte hydrazongruppen enthaltende kuppler
EP1447099B1 (de) Antineoplastisch wirkende Polyethylenkonjugate zytostatischer Verbindungen und diese enthaltende Arzneimittel
DE69429689T2 (de) Durch lysosomale Enzyme spaltbare Antitumor-Wirkstoff-Konjugate
DE69333800T2 (de) Thioether enthaltende Konjugate
DE60031793T2 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
DE68912232T2 (de) Konjugate zytotoxischer Arzneimittel.
DE69614551T2 (de) Verfahren zur herstellung von monomeren calicheamicinderivaten/trägerkonjugaten
DE69118350T2 (de) Linker für bioaktive mittel
DE3685625T2 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
EP1594548B1 (en) Anthracycline-anti-cd74 antibody conjugates
DE69528016T2 (de) Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung
DE68924783T2 (de) Wässrige additivsysteme, verfahren und polymerteilchen.
JPH03161490A (ja) メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
DE69030213T2 (de) Anthracyclin-Konjugate mit einem neuen Linker und Verfahren zu dessen Herstellung
DE69907419T2 (de) Antitumorwirkstoffe
DE3851682T2 (de) Targetformer von Antitumor-Methyltrithioagenzien.
DE69125707T2 (de) Anthracyclinkonjugate
DE102016105449A1 (de) Bifunktionale Prodrugs
KR910007977B1 (ko) 항종양 전구약물
AU2022451890A1 (en) Conjugate for targeting therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee